Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Rapt Therapeutics (RAPT) to $38 from $51 and keeps an Overweight rating on the shares. The firm sees potential for value inflection in RAPT shares in the second half of 2025 upon partner Jemincare’s China study readouts in lateral indications if RPT904 could show better PD and/or efficacy than Xolair in related indications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics: Anticipated Growth Driven by Strategic Partnerships and Promising Clinical Developments
- Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges
- RAPT Therapeutics Reports Q2 2025 Financial Results
- RAPT Therapeutics’ RPT904: A Promising Catalyst with Competitive Edge in the Anti-IgE Market
- Rapt Therapeutics reports Q2 EPS (65c), consensus (65c)